CBD May Reduce Pain Sensitivity Differently Depending on Opioid Treatment Type | Research

The takeaway

In a small proof-of-concept study, CBD improved heat pain tolerance in patients on buprenorphine but not methadone for opioid use disorder, with no serious adverse events at any dose.

Patients in opioid treatment programs with chronic pain, addiction medicine specialists, and researchers studying CBD for pain management.

What the researchers found

CBD showed a significant interaction with medication type for heat pain measures: buprenorphine patients had significantly higher heat pain threshold (at 400mg CBD) and heat tolerance (at 800mg CBD) compared to methadone patients. The 400mg dose showed the most favorable pain response pattern in the buprenorphine group. CBD was well-tolerated at all doses (400-1200mg).

Why it matters

Pain management in opioid use disorder patients is extremely challenging — they need pain relief but are vulnerable to opioid misuse. CBD could offer a non-opioid option, and this study suggests it may work especially well alongside buprenorphine treatment.

The numbers in context

7 participants. 3 CBD doses tested: 400mg, 800mg, 1200mg. Significant MOUD×CBD dose interaction for heat pain threshold and tolerance. 400mg CBD showed best response in buprenorphine group. No serious adverse events at any dose. No cognitive effects on verbal memory.

How the study worked

Open-label, proof-of-concept study with 7 individuals receiving methadone or buprenorphine for opioid use disorder with chronic pain. Three test sessions with ascending oral CBD doses (400mg, 800mg, 1200mg). Quantitative sensory testing (QST) used to assess pain sensitivity. Safety and tolerability monitored.

What this study cannot tell us

Extremely small sample (n=7). Open-label design (no placebo control). Cannot generalize from so few participants. Ascending dose design means order effects can't be separated from dose effects. Short-term testing only.

How to read the evidence

Very small open-label proof-of-concept (n=7) — hypothesis-generating only, not sufficient for clinical recommendations.

When this study was published

Published in 2026, addressing a critical gap in non-opioid pain management for addiction patients.

The bigger picture

The opioid crisis has created urgent need for non-addictive pain treatments, especially for people already struggling with opioid use disorder. The finding that CBD's effects depend on which opioid medication someone takes could personalize pain management approaches.

Questions still open

Why does CBD appear to work differently with buprenorphine vs. methadone? Would a larger placebo-controlled trial confirm these findings? What is the optimal CBD dose for pain management in OUD patients?

Common questions

Could CBD help with pain in people recovering from opioid addiction?

This tiny pilot study (7 people) found promising signals that CBD may improve pain tolerance specifically in patients taking buprenorphine for opioid use disorder. However, much larger trials are needed before any clinical recommendations.

Is CBD safe to take with opioid treatment medications?

In this study, CBD up to 1200mg was well-tolerated alongside both methadone and buprenorphine, with no serious adverse events or cognitive effects. However, the sample was very small, and patients should always consult their provider.

Read the original research

Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study.

Addictive behaviors reports, 23, 100654

View on PubMed ↗Publisher’s paper ↗

Citation

Costa, Gabriel P A; Suh, Rebecca; Sofuoglu, Mehmet; De Aquino, Joao P. (2026). Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study.. Addictive behaviors reports, 23, 100654. https://doi.org/10.1016/j.abrep.2025.100654